The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Propensity Score Methods for Analyzing Observational Data Like Randomized Experiments: Challenges and Solutions for Rare Outcomes and Exposures

(2015) M. E. Ross et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan forHelicobacter pylori

(2015) Koji Kamiya et al.   JOURNAL OF DERMATOLOGY

Sequential or concomitant therapy for eradication ofHelicobacter pyloriinfection: A systematic review and meta-analysis

(2015) Joon Sung Kim et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Concomitant therapy achieved the best eradication rate forHelicobacter pyloriamong various treatment strategies

(2015) Hyun Jeong Lee   WORLD JOURNAL OF GASTROENTEROLOGY

A Comparative Study of Sequential Therapy and Standard Triple Therapy for Helicobacter pylori Infection: A Randomized Multicenter Trial

(2014) Liya Zhou et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pretreatment Antimicrobial Susceptibility-Guided Vs. Clarithromycin-Based Triple Therapy for Helicobacter pylori Eradication in a Region With High Rates of Multiple Drug Resistance

(2014) Chung-Su Park et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Factors Affecting First-Line Triple Therapy of Helicobacter pylori Including CYP2C19 Genotype and Antibiotic Resistance

(2014) Ju Yup Lee et al.   DIGESTIVE DISEASES AND SCIENCES

The efficacy of hybrid therapy as first-line regimen forHelicobacter pyloriinfection compared with sequential therapy

(2014) Dong Hyun Oh et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Comparative study of esomeprazole and lansoprazole in triple therapy for eradication ofHelicobacter pyloriin Japan

(2014) Tsutomu Nishida   WORLD JOURNAL OF GASTROENTEROLOGY

Meta-analysis: Can Helicobacter pylori Eradication Treatment Reduce the Risk for Gastric Cancer?

(2013) Lorenzo Fuccio et al.   ANNALS OF INTERNAL MEDICINE

Effects of CYP2C19 Loss-of-Function Variants on the Eradication of H. pylori Infection in Patients Treated with Proton Pump Inhibitor-Based Triple Therapy Regimens: A Meta-Analysis of Randomized Clinical Trials

(2013) Hui-Lin Tang et al.   PLoS One

Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot study

(2013) Angelo Zullo et al.   Clinics and Research in Hepatology and Gastroenterology

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

(2012) A. G. McNicholl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory

(2012) Charles M. Strom et al.   GENETICS IN MEDICINE

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Prevalence of Primary and Secondary Antimicrobial Resistance ofHelicobacter pyloriin Korea from 2003 through 2012

(2012) Jung Won Lee et al.   HELICOBACTER

Ten-day sequentialversustriple therapy forHelicobacter pylorieradication: A prospective, open-label, randomized trial

(2012) Jun-Won Chung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

The in vitro diagnosis of drug allergy: status and perspectives

(2011) D. G. Ebo et al.   ALLERGY

A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands

(2011) Jun Matsukawa et al.   BIOCHEMICAL PHARMACOLOGY

A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan

(2011) Toshio Fujioka et al.   JOURNAL OF GASTROENTEROLOGY

A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals

(2011) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Aluminiumper seand in the anti-acid drug sucralfate promotes sensitization via the oral route

(2009) R. Brunner et al.   ALLERGY

Suppression of gastric acid increases the risk of developing Immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model

(2009) A. B. Riemer et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Long-lasting inhibitors of the gastric H,K-ATPase

(2009) Jai Moo Shin et al.   Expert Review of Clinical Pharmacology

Acid peptic diseases: pharmacological approach to treatment

(2009) Alex Mejia et al.   Expert Review of Clinical Pharmacology